Jakob Starup-Linde

Jakob Starup-Linde

Auto-generated profile, based on publicly available information

Jakob Starup-Linde

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
KHKatrine Hygum
Katrine Hygum
JSJakob Starup-Linde
Jakob Starup-Linde
THTorben Harsløf
Torben Harsløf
PVPeter Vestergaard
Peter Vestergaard
BLBente L Langdahl
Bente L Langdahl
Objective To investigate the differences in bone turnover between diabetic patients and controls. Design A systematic review and meta-analysis. Methods A literature search was conducted using the databases Medline at PubMed and EMBASE. The free text search terms ‘diabetes mellitus’ and ‘bone turnover’, ‘sclerostin’, ‘RANKL’, ‘osteoprotegerin’, ‘tartrate-resistant acid’ and ‘TRAP’ were used. Studies were eligible if they investigated bone turnover markers in patients with diabetes compared with controls. Data were extracted by two reviewers. Results A total of 2881 papers were identified of which 66 studies were included. Serum levels of the bone resorption marker C-terminal cross-linked telopeptide (−0.10 ng/mL (−0.12, −0.08)) and the bone formation markers osteocalcin (−2.51 ng/mL (−3.01, −2.01)) and procollagen type 1 amino terminal propeptide (−10.80 ng/mL (−12.83, −8.77)) were all lower in patients with diabetes compared with controls. Furthermore, s-tartrate-resistant acid phosphatase was decreased in patients with type 2 diabetes (−0.31 U/L (−0.56, −0.05)) compared with controls. S-sclerostin was significantly higher in patients with type 2 diabetes (14.92 pmol/L (3.12, 26.72)) and patients with type 1 diabetes (3.24 pmol/L (1.52, 4.96)) compared with controls. Also, s-osteoprotegerin was increased among patients with diabetes compared with controls (2.67 pmol/L (0.21, 5.14)). Conclusions Markers of both bone formation and bone resorption are decreased in patients with diabetes. This suggests that diabetes mellitus is a state of low bone turnover, which in turn may lead to more fragile bone. Altered levels of sclerostin and osteoprotegerin may be responsible for this.

1 January 2016 in Bone
Verified
Journal Article
Closed access
JSJakob Starup-Linde
Jakob Starup-Linde
PVPeter Vestergaard
Peter Vestergaard

28 March 2014 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
JSJ. Starup-Linde
J. Starup-Linde
SES. A. Eriksen
S. A. Eriksen
SLS. Lykkeboe
S. Lykkeboe
AHAase Handberg
Aase Handberg
PVP. Vestergaard
P. Vestergaard

31 December 2013 in Current Drug Safety
Verified
Journal Article
Open access
PDF file
OKOystein Karlstad
Oystein Karlstad
JLJacob Starup Linde
Jacob Starup Linde
PVPeter Vestergaard
Peter Vestergaard
VHVidar Hjellvik
Vidar Hjellvik
MBMarloes T Bazelier
Marloes T Bazelier
MBMarie L De Bruin
Marie L De Bruin
Background: An association of insulin use and risk of cancer has been reported but evidence is conflicting and methodological issues have been identified. Objective: To summarize results regarding insulin use and cancer risk by a systematic review and meta-analysis of cohort and case-control studies examining risk of cancer associated with insulin use in patients with diabetes. Data Sources: Systematic literature search in 5 databases: PubMed, Embase, Web of Science, Scopus and Cochrane Library. Study Eligibility Criteria (PICOS): Population: diabetes patients. Exposure: Users of any exogenous insulin. Comparison: Diabetes patients with or without use of antidiabetic drugs. Outcome: Any incident cancer. Study Design: Cohort and case-control studies. Results: 42 eligible studies examined risk of any cancer and 27 site-specific cancers. Results of individual studies were heterogeneous. Meta-analyses were significant for: Insulin vs No Insulin: Increased risk for pancreas, liver, kidney, stomach and respiratory cancer, decreased risk for prostate cancer. Insulin vs Non-Insulin Antidiabetics: Increased risk for any, pancreatic and colorectal cancer. Glargine vs Non-Glargine Insulin: Increased risk for breast cancer, decreased risk for colon cancer. Limitations: Few studies available for most cancer sites and exposure contrasts, and few assess effect of dose and duration of exposure. Methodological issues in several studies. Availability of confounders. Conclusions: Insulin use was associated with risk of cancer at several sites. Cautious interpretation of results is warranted as methodological issues and limitations in several of the included studies have been identified. Choice of study design may have a profound effect on estimated cancer risk.

14 March 2017 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
AOA. G. Olsson
A. G. Olsson
BAB. Angelin
B. Angelin
GAG. Assmann
G. Assmann
CBC. J. Binder
C. J. Binder
IBI. Björkhem
I. Björkhem
LYLaurent Yvan-Charvet
Laurent Yvan-Charvet
Following the continuous accumulation of evidence supporting the beneficial role of reducing low‐density lipoprotein cholesterol (LDL‐C) levels in the treatment and prevention of atherosclerotic cardiovascular disease and its complications, therapeutic possibilities now exist to lower LDL‐C to very low levels, similar to or even lower than those seen in newborns and nonhuman species. In addition to the important task of evaluating potential side effects of such treatments, the question arises whether extremely low LDL‐C levels per se may provoke adverse effects in humans. In this review, we summarize information from studies of human cellular and organ physiology, phenotypic characterization of rare genetic diseases of lipid metabolism, and experience from clinical trials. Specifically, we emphasize the importance of the robustness of the regulatory systems that maintain balanced fluxes and levels of cholesterol at both cellular and organismal levels. Even at extremely low LDL‐C levels, critical capacities of steroid hormone and bile acid production are preserved, and the presence of a cholesterol blood–brain barrier protects cells in the central nervous system. Apparent relationships sometimes reported between less pronounced low LDL‐C levels and disease states such as cancer, depression, infectious disease and others can generally be explained as secondary phenomena. Drug‐related side effects including an increased propensity for development of type 2 diabetes occur during statin treatment, whilst further evaluation of more potent LDL‐lowering treatments such as PCSK9 inhibitors is needed. Experience from the recently reported and ongoing large event‐driven trials are of great interest, and further evaluation including careful analysis of cognitive functions will be important.

1 January 2013 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
JSJakob Starup-Linde
Jakob Starup-Linde
Diabetes mellitus is known to have late complications including micro vascular and macro vascular disease. This review focuses on another possible area of complication regarding diabetes; bone. Diabetes may affect bone via bone structure, bone density, and biochemical markers of bone turnover. The aim of the present review is to examine in vivo from humans on biochemical markers of bone turnover in diabetics compared to non-diabetics. Furthermore, the effect of glycemic control on bone markers and the similarities and differences of type 1- and type 2-diabetics regarding bone markers will be evaluated. A systematic literature search was conducted using PubMed, Embase, Cinahl, and SveMed+ with the search terms: “Diabetes mellitus,” “Diabetes mellitus type 1,” “Insulin dependent diabetes mellitus,” “Diabetes mellitus type 2,” “Non-insulin dependent diabetes mellitus,” “Bone,” “Bone and Bones,” “Bone diseases,” “Bone turnover,” “Hemoglobin A Glycosylated,” and “HbA1C.” After removing duplicates from this search 1,188 records were screened by title and abstract and 75 records were assessed by full text for inclusion in the review. In the end 43 records were chosen. Bone formation and resorption markers are investigated as well as bone regulating systems. T1D is found to have lower osteocalcin and CTX, while osteocalcin and tartrate-resistant acid are found to be lower in T2D, and sclerostin is increased and collagen turnover markers altered. Other bone turnover markers do not seem to be altered in T1D or T2D. A major problem is the lack of histomorphometric studies in humans linking changes in turnover markers to actual changes in bone turnover and further research is needed to strengthen this link.